Northern Illinois University

Huskie Commons
Graduate Research Theses & Dissertations

Graduate Research & Artistry

2016

Simulation analysis of blood flow and selective drug particle
delivery to the targeted tumors cerebral artery-tissue region
Sravanthi Patibandla

Follow this and additional works at: https://huskiecommons.lib.niu.edu/allgraduate-thesesdissertations

Recommended Citation
Patibandla, Sravanthi, "Simulation analysis of blood flow and selective drug particle delivery to the
targeted tumors cerebral artery-tissue region" (2016). Graduate Research Theses & Dissertations. 4920.
https://huskiecommons.lib.niu.edu/allgraduate-thesesdissertations/4920

This Dissertation/Thesis is brought to you for free and open access by the Graduate Research & Artistry at Huskie
Commons. It has been accepted for inclusion in Graduate Research Theses & Dissertations by an authorized
administrator of Huskie Commons. For more information, please contact jschumacher@niu.edu.

ABSTRACT

SIMULATION ANALYSIS OF BLOOD FLOW AND SELECTIVE DRUG PARTICLE
DELIVERY TO THE TARGETED TUMOR’S CEREBRAL ARTERY-TISSUE REGION
Sravanthi Patibandla, MS
Department of Mechanical Engineering
Northern Illinois University, 2016
Pradip Majumdar, Director

Brain is the most intricate organ of human body. The development of new therapeutic
techniques for brain tumor diseases is a difficult task, yet these treatments are not effective for
almost all the brain diseases. Presence of blood brain barrier (BBB) is the main challenge in
development of drugs to treat brain diseases in most of the cases. Among several brain diseases,
brain tumors often have poor prognosis, which depends and changes according to the type of the
tumor.
In this study a three-dimensional computational simulation model for analyzing
multifunctional drug distribution through the cerebral artery and adjacent tissue region with tumor
is considered. The simulation model includes solution of governing equations of blood flow
dynamics based on Navier-Stokes equations and mass species transport based on Lagrangian
particle flow dynamics in the artery network and capillaries of the adjacent tissue-tumor regions
subjected to typical cardiac cycle. The main objective is to evaluate the effective delivery of
selective drug particles to the targeted tumor region with variation in the selective multifunctional
particle types and sizes.
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Chapter 1: INTRODUCTION
1.1 Introduction
Brain tumors are identified as growth of abnormal cells in the brain. Most of the brain
tumors are malignant brain tumors and about 650 people are identified with this type of brain
tumor every day [1]. Brain tumors affect human health to greater extent due to their quick
development and poor prognosis. There are various options like chemotherapy and targeted
therapy available for treating brain tumors. Blood-brain barrier (BBB) is the one that protects
brain and it separates the circulating blood from brain extracellular fluid and this barrier allows
only some kind of antibiotics.

Current research is being carried out in developing the

multifunctional drug targeting efficiency by changing parameters such as polymer coatings over
drug and particle diameter so that it targets the tumor region.
1.2 Literature Review
Kumar Bishwajit Sutradhar and Md. Lutful Amin [2] describe specific drug delivery by
nanoparticles to affected tumor region by two various methods: active targeting and passive
targeting.
Bhaskar’s article [3] focus on structural composition of drug such that it passes over BBB
(blood-brain barrier).
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Kumaresh S. Soppimath [4] gives the information about the use of biodegradable
polymeric nanoparticles as drug delivery system.
Khaled and Vafai [5] explain and derive various models available for setting porous
medium for biological tissues. Transport in porous media is explained using mass diffusion and
different convective models.
Caixia Ding [6] discuss the effect of pH during drug delivery. The pH value of solid
tumors is 6.8 (slightly acidic) when compared with the physiological pH (7.4).
Massimo Masserini [7] shows the treatment of tumors is obstructed by the presence of
blood-brain barrier (BBB), overcome by most available effective drugs. Therefore, the invention
and development of novel drug delivery systems for the treatment of brain tumors is a major
challenge for both the academic and pharmaceutical community. Nanotechnology is a promising
approach where different types of nanoparticles are available for biomedical use with different
characteristics and applications enabling the delivery of drugs to target region.
Shafiullah’s study [8] is an analysis of blood in a straight artery with a branched structure
with and without stenosis. This study was helpful for setting up the physics model for CFD analysis
using star CCM+.
Narmada’s study [9] extended the Shafiullah’s 2-D model of branched straight artery to
a much more realistic artery with curvature considered from the CT scan of atherosclerosis
patient. She considered porous medium for tissue region which is based on Darcy’s principle
and analyzed the pulsatile blood flow for different stages of the disease. This study helped me
for setting up the porosity values for tissue and tumor regions.
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Sindhuja Moda [10] also observed drug concentration distribution through the cerebral
artery and adjacent imaginary tissue region with tumor and realistic tissue region.
1.3 Objective
The objective of this study is to develop a simulation analysis model for analyzing
multifunctional and selective drug particle delivery to a targeted tissue-tumor region. In this study
a three-dimensional computational simulation model for analyzing multifunctional drug
distribution through the cerebral artery and adjacent tissue-tumor region with is considered.
The simulation model includes solution of governing equations of blood flow dynamics
based on Navier-Stokes equations and mass species transport based on Lagrangian particle flow
dynamics in the artery network and capillaries of the adjacent tissue-tumor regions subjected to
typical cardiac cycle.
The simulation analysis is performed to evaluate and analyze the drug particle distributions
and consumptions around the targeted region with varying particle sizes and concentrations. The
main objective of this study is to evaluate and optimize the effectiveness of the drug delivery to
the targeted tumor region with variation in the selective multifunctional particle types, size and
dose concentrations.

Chapter 2: PHYSICAL DESCRIPTION OF THE MODEL
In this chapter, brief description of the model (i.e., geometry, governing equations
including boundary conditions, drug and polymer used) is discussed.
2.1 Artery – Capillary Network
This network is a part of the circulatory system consisting of the arteries, capillaries and
veins which are connected to the heart. According to the blood circulatory system, the blood for
the heart is pumped through the arteries, which carry the blood to the capillary (Figure 1). At the
capillary the gas exchange occurs and the used blood is then pumped back to the heart with the
help of veins.

HEART

VEINS

ARTERY

CAPILLARY
Figure 1 : Schematic Diagram of Circulatory System
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Artery:
Arteries carry oxygenated blood from heart to all the body parts. During the circulation
of the blood high pressure is exerted on its walls; in order to withstand this high pressure, artery
walls are elastic, thicker and muscular. Muscular nature offers smoothness to the arteries which
allows for expansion and contraction accordingly, resulting in regulating the blood flow.
Capillary:
These are the smallest blood vessels in the body which connect to various organs of the
entire body. It has a thin permeable layer called endothelium, which acts as the barrier between
the tissues and the blood in capillaries. This permeable layer helps in the exchange of the nutrients
and oxygen as energy to the tissues. Also the waste gases are in turn taken out from the tissue and
carried away by the blood through this layer in capillaries. The exhaust derived from the tissues
is carried to veins from capillaries.
Veins:
Deoxygenated blood from the capillaries is carried back to heart by veins. Veins are
thinner and less elastic in nature. The mechanism employed in pumping the blood back to the heart
depends on the inertia, gravity and the muscle contraction force. This contraction force helps in
forcing blood to the heart.
2.1.1 Geometry
A three dimensional artery with capillary and the tissue-tumor region of brain, using the
CT and MRI scan images of tumor-affected patient, is designed using SpaceClaim [10]. Artery of
length 11 mm and diameter 5mm, capillaries of length 5mm and diameter 1.5 mm, an area of 340
mm^2 and 120 mm^2 for tissue and tumor region were considered as shown in Figure 2.

6

Figure 2 : Three Dimensional Design Model
The cerebral artery was modeled considering a CT scan image of a 62-year-old human.
Although the CT scan image shows large number of capillaries connected in the brain, only a
partial image is considered to simplify the modelling. The initial step in design process is to
import the image into the design window and splines are created to selected partial image. Then
the splines are linked to form a 2-D planar image. SpaceClaim is used for designing which has
the distinctive feature of prompting the 3-D plane to the complex curvature. Using the 3-D plane
and the sweep options, the 3-D model is designed as shown in the Figure 2. A circular tissue and
tumor are designed to the artery capillary unit using Hyper Mesh. The same software is used to
generate mesh [10].

2.2 Cardiac Cycle
Cardiac cycle explains the mechanism of heart employed during the circulation of the
blood. The cardiac cycle has two phases, diastole and systole (Figure 3). Systole phase begins with
the contraction of the ventricles, causing the blood to be ejected with a high pressure. The
velocity in this phase reaches a peak velocity due to high pressure exerted during contraction.
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As relaxation of ventricles starts there is sudden drop in velocity. Diastole phase starts when the
ventricles relax after the ejection of blood. The blood starts to fill after sufficient relaxation as
the heart expands in this phase.

Figure 3 : Block Diagram of Cardiac Cycle
The flow velocity with respect to time is as shown in Figure 4 where VF indicates systolic
forward peak velocity, VR represents reverse peak velocity, VF2 is diastolic forward peak velocity,
VM indicates time-averaged mean velocity and VD is end diastolic velocity [11]. See Table 1.

Figure 4 : Inlet Flow Velocity vs Time
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Table 1 : Waveform Range Values
Variable
Systolic forward peak velocity (Vf)

Velocity range (cm/sec)
69±19

Diastolic reverse peak velocity
-19±6
End diastolic velocity (Vd)
8±4
Time-averaged mean velocity (Vm) 1±3

2.3 Governing Equations
Governing equations are the equations that describe the behavior of a system in terms of
its motion as a function of time. These equations specifically describe the behavior of a system as
a set of functions in terms of dynamic variables like spatial coordinates, time, momentum
components and many others. The fundamental governing equations for blood and drug flow are
discussed in this section.
2.3.1 Navier-Stokes Equation
Navier–Stokes equations are useful as they define the physics of several phenomena
of scientific and engineering importance. Some assumptions are made such as continuous media,
viscous constant, incompressible fluid, implicit unsteady, constant density, laminar, and
segregated flow.
The Navier-Stokes equation for incompressible flow is used to govern the motion of the
fluid. The following is the Navier-Stokes equation used for the analysis of blood flow for
Newtonian model:
𝜌(

𝜕𝑢
+ (𝑢. ∇)𝑢) = −∇𝑝 + μ. ∇2 𝑢 + 𝑔
𝜕𝑡
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where 𝑢 is the fluid velocity, 𝑝 is the fluid pressure, 𝜌 is the fluid density, 𝑔 is gravity and μ is the
fluid dynamic viscosity. And also

𝜕𝑢
𝜕𝑡

is variation, (𝑢. ∇)𝑢 and μ. ∇2 𝑢 are convection and diffusion

terms, −∇𝑝 is internal source and 𝑔 is external source term, and

𝜕𝑢
𝜕𝑡

+ (𝑢. ∇)𝑢 is inertia term.

For non-Newtonian fluid with varying viscosity, the following is the Navier-Stokes
equation used for the analysis of blood flow:
𝜕𝑢

𝜌(

𝜕𝑡

+ (𝑢. ∇)𝑢) = −∇𝑝 + ∇(𝜂(∇𝑢 + (∇𝑢)𝑇 )

2.3.1.1 Boundary Conditions
The subject of appropriate and precise boundary conditions or the initial conditions in
computational fluid dynamics is very important. These conditions describe the detailed solutions
to be gotten from the governing equations.
Velocity Inlet: All inlets in model are velocity inlets and a set of tabulated values are given as
velocity input which follows the cardiac cycle as shown in Figure 4 that was calculated by
Hashimoto and Ito [11].
Pressure Outlet: All the outlets for the artery and venule are considered as pressure outlets
and set to zero pressure conditions.
2.3.2 Tissue-Region Porous Media Model
Porosity is the physical property of a material having pores on its structure that allow
liquids to flow through it. Tissues are considered to be porous as they are composed of cells that
are separated by voids, which allow for exchange of nutrients and minerals to all the cells.
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The flow and transport of mass species in porous biological tissue region is primarily dominated
by transport model involving pressure, viscous, and inertial forces. One of the simplest models for
flow transport in porous media is the Darcy model given as
𝑣=−

𝐾
∇𝑃
𝜇

v =Velocity
P =Pressure Gradient
µ =Viscosity of Blood
K = Permeability Coefficient
The model in Darcy drag resistance neglects convective term and works well for
unbounded regions, neglecting boundary effects on the flow.
Brinkman’s flow model is a generalized Darcy model that takes into account of the
boundary effect and has been used in many biological porous regions [5]. In this study, the blood
flow and drug transport in the porous regions for both the tissue and tumor regions is model by the
Brinkman’s model given as
∇𝑃 = −

𝜇
𝑣 + 𝜇̃ ∇2 𝑣
𝐾

where 𝜇̃ is effective dynamic viscosity, 𝜇 is dynamic viscosity of the fluid (i.e., blood in
this case), 𝑣 is the velocity of the fluid, ∇𝑃 is pressure gradient vector and 𝐾 is permeability of the
porous medium. The first term on the right-hand side is the Darcy’s viscous term and the second
term represents the viscous diffusion term similar to that in Navier-Stokes equation. This model
also neglects the convective terms.
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2.3.3 Lagrangian Flow Model
In Lagrangian flow model, the flow of particles is considered as the dispersed phase and
the particle tracking with respect to its path is considered individually [10]. This flow model is
good for this study and is used for the flow of drug particles. The Lagrangian governing equation
used is shown below:
d𝑈𝑃
g(𝜌𝑃 − ρ)
= F (u − 𝑈𝑃 ) +
dT
𝜌𝑃
where 𝑈𝑃 is particle velocity vector, 𝜌𝑃 is particle density, 𝐹1 is additional forces, 𝐹 is
Inverse of relaxation time, g is gravity and u is fluid velocity. The shape of the particle considered
for this study is spherical with varying diameters. The first term on left side is inertial force per
unit mass and the first term on right side is drag term; second term represents gravity, buoyancy.
2.3.4 Coupling
Coupling is a phenomenon used when there are different types of materials which need to
be combined together for obtaining an accurate solution. In this case, there are two mediums like
the blood which is a liquid and drug particles that are immersed in the fluid. In order to obtain the
combined behavior of this, the Navier-Stokes equation is coupled with the Lagrangian equation.
2.3.5 Mass Species Transport for Drug Concentration
𝜕(ρϕ𝑑 )
+ 𝑑𝑖𝑣(ρϕ𝑑 u) = 𝑑𝑖𝑣 (Γ grad(ϕ𝑑 )) + Sϕ𝑑
𝜕t
where
ϕ𝑑 is drug species concentration
u is velocity vector and
Γ is diffusivity term.
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𝑆ϕ𝑑 is source and consumption of drug:
𝑆ϕ𝑑 = 𝑚̇′′′ ϕ𝑑
Source term is manipulated to explain the drug consumption.

2.4 Role of Polymers in Drug Delivery
This section describes the role of polymers used in drug delivery of therapeutic agents. The
polymers are used to deliver the drug to the target region. Biodegradable polymers are generally
used to deliver the drugs to a specific region of the body as they degrade with a constant rate of
drug release. The process used for the release of drug from the polymers is either by degradation
or diffusion. They are used as binders, as film coating over the drug, to improve the stability and
alter the release characteristics of the drug at the targeted site [12].
There are few drugs used for treating brain tumors. Among them Temozolomide is the drug
used for this study. The molecular formula is 𝐶6 𝐻6 𝑁6 𝑂2 with a density of 1970 kg/m^3.
Polyethylene glycol (PEG) with a density of 1260 kg/m^3 is used for the drug coating such that it
penetrates into the blood-brain barrier. According to the structural organization, nanoparticles are
of two types: nanocapsule and nanoshpere as shown in Figure 5. In nanocapsule the drug particles
are within a closed polymeric membrane, whereas in nanoshpere the drug particles are distributed
in the polymeric matrix. For this we considered nanocapsule where the drug Temozolomide is
coated with PEG layer with varying particle diameter and increasing coating over the particle.
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Figure 5 : Schematic Representation of Nanocapsule and Nanosphere
(https://www.researchgate.net/figure/236089851_fig3_FIG-3)

2.5 Effect of pH
The final goal of drug delivery is to attain a desired therapeutic concentration at the
targeting tumor while the drug concentrations at other tissue regions are at safe levels. Therefore,
multifunctional drug carriers have the ability to interact with different biological membranes with
the change of environmental conditions during the entire delivery procedure [6]. Surface charge
conversion of a drug carrier in response to the change of external pH around 6.8-7.4 would also
help to deliver the drug to targeting tumor region, since the solid tumors is slightly acidic with pH
of 6.8 when compared with the physiological pH of 7.4 and multifunctional antitumor drug
delivery systems have a pH range of 5.0 – 6.5 [6].

2.6 Design and Formulation of Multifunctional Drug Particles
Over the recent years, the polymer-based drugs have been emerging as a promising
therapeutic method to treat various diseases (Figure 6). Various polymer drug delivery systems are
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presently approved in treating cancer effectively compared to conventional drugs. Studies have
proved that integrating low molecular mass drugs into polymers increases drug solubility and
stability, and accumulates drugs in solid tumors, thus reducing the side effects. Multifunctional
particle composed of drugs encapsulated with a layer of polymer coating makes the particle a
carrier and prevents from dissolving in bloodstream. It keeps the drug concentrations at other tissue
regions at safe levels.

Figure 6 : Schematic Representation of Polymer Coating over Drug
2.6.1 Combined Density and Size
Combined density is calculated using the following formulation:

𝑚𝑠 = 𝑚𝑠𝑑 + 𝑚𝑠𝑝

𝑚𝑠𝑑 = 𝜌𝑑 𝑣𝑖

𝑚𝑠𝑝 = 𝜌𝑝 𝑣𝑝

𝑣𝑝 = 𝑣𝑜 − 𝑣𝑖

4
𝑣𝑜 = 𝜋𝑟𝑜3
3

4
𝑣𝑖 = 𝜋𝑟𝑖3
3

∅𝑠 =

𝑚𝑠𝑑
𝑚𝑠

𝜌 = ∅𝑠 𝜌𝑑 + (1 − ∅𝑠 )𝜌𝑝
where 𝑚𝑠 is total mass (kg), 𝑚𝑠𝑑 is mass of the drug (kg), 𝑚𝑠𝑝 is mass of the polymer
(kg), 𝑟𝑜 is outer radius (m), 𝑟𝑖 is inner radius i.e., radius of drug particle (m), and 𝜌 is combined
density (kg/m^3).

Chapter 3: CFD MODEL
3.1 Simulation Model
This section describes about the suitable model of the flow. The flow of the blood is
considered as non-Newtonian with varying viscosity input: implicit unsteady, constant density,
laminar, and segregated flow. Drug flow is assumed as multiphase, Lagrangian model, injectors,
spherical particles, liquid, density, and particle dimensions.
The geometry model that is designed using SpaceClaim is imported into Fluent software
and assigned all inlets and outlets as shown in Figure 7.

Figure 7 : Geometry Model Showing Inlets and Outlets
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3.2 Mesh
In computational solutions of the governing equations, meshing is a discretization of the
geometry into subdomains that are involved in the problem over which the equations can be
estimated. The accurate solution can be achieved faster with better mesh quality and a
greater rate of convergence.
Mesh is generated as shown in Figure 8, with node values of 405257, 125087, 385455, and
849953 for arteries, capillaries, tumor, and tissue respectively using the surface remesher, prism
layer mesher, and trimmer models with a base size of 0.3 and three prism layers.

Figure 8 : Preview of Mesh

3.3 Input Value Conditions at Artery
Velocity inlet with transient velocity data input: The set of tabulated values is given as input
velocity table for inlet of artery. This velocity table is observed from the waveform calculated by
Hashimoto and Ito [11] .
Drug flow rate as another input: To set the particle flow for analyzing the drug concentration
distribution, Lagrangian multiphase flow is considered. A separate physics is set for analyzing the
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particle flow in the arterycapillary-tissue-tumor network. The flow rate is given an inlet to the
artery using Lagrangian injectors. Also particle specifications such as diameters shape are
indicated.

3.4 Unsteady Computational Parameters:
Simulation executes by considering the segregated flow solver which solves the flow
equations. First order discretization is used to solve and results are taken at different time steps
with the maximum physical time of 0.25sec, time step of 0.01sec and 50 inner iterations for each
time step. Also, under relaxation factors of 0.7 and 0.3 are considered for velocity and pressure
respectively [8].

3.5 Computational Data
The tissue and tumor regions are considered as porous regions. A porosity of 0.3, 0.2 is
taken for tissue and tumor respectively. A higher porosity value for tissue is because the tissue
region is less resistant than tumor region. By using formulation that is discussed in Section 2.6,
combined densities are calculated and represented in Table 2.
Table 2 : Combined Density for Various Drug-Polymer Coating Ratios
Ratio(D:P)
(volume)

Size before
coating(microns)

Density(kg/m3)

Size after
coating(microns)

1:8

1294.8

0.05

0.1

1:65

1148.8

0.05

0.2

1:120

1137.7

0.05

0.25
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Mass source is activated at tumor region for reducing the particle count by giving negative
mass source term value. Two cases are considered, 80% and 50% of total density and is converted
into kg/m^3-s as shown in Table 3.

Table 3 : Mass Source Term Values
Density

1970 kg/m^3

32.833 kg/m^3-s

50 %

985 kg/m^3

16.41666 kg/m^3-s

80%

1576 kg/m^3

26.266 kg/m^3-s

Chapter 4: RESULTS AND DISCUSSIONS
The computational simulation model is used to find the velocity and particle volume in
the flow of blood with respect to the cardiac cycle. Further particle distribution of drug into the
targeted tumor region is observed in terms of velocities and particle volume with which drug
reaches the tumor by varying particle size and polymer coating. Mass source is activated at tumor
region to reduce the particle flow at tumor region to explain uptake of the drug at target region.
4.1 Velocity Distribution in Brain Tissue Region
Three line probes are drawn at different positions such as bottom, top and center of the
tumor as shown in Figure 9 and velocity along these line probes is observed.

Bottom of the Tumor

Top of the Tumor

Along of the Tumor

Figure 9 : Velocity Distribution Plot in Brain Tissue Region

20
The blood flow is unevenly distributed due to the highly heterogeneous and anisotropic
nature of the region. The flow is further complicated due to presence of the tumor. The results show
a dominant blood flow through the bottom region compared to top region around the tumor. Flow
is significantly reduced and slow in the tumor region because of high resistance. Flow is also highly
modulating before and after the tumor region due to cyclic nature of the inlet cardiac flow condition.

4.2 Drug Flow Distribution in Cerebral Artery and Tissue Region for 50nm Size
The Figure 10 shows the flow of drug particle at increasing time steps, i.e., at 0.072 sec,
0.076 sec, 0.081 sec and 0.095 sec.

0.072 sec

0.081 sec

Figure 10 : Drug Particle Flow at Various Time

0.076 sec

0.095sec
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The drug particle reaches the tumor at 0.081 sec and dosage of drug increases continuously
following cardiac cycle. However the flow velocity of blood tissue and tumor regions is less
compared to artery region because there is obstruction for the flow of the blood at the tissue-tumor
region.

4.3 Drug Flow Distribution in Cerebral Artery and Tissue Region at Different Times
with Varying Sizes
In this section, velocity distribution is discussed by varying particle diameter. This
variation can be seen for particle size of 20nm, 30nm and 50nm (Figures 11-13).

0.1sec

0.125sec

0.2sec

0.25sec

Figure 11 : Velocity Distribution for Particle Size of 20 nm
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The Figure 11 shows the flow of drug particle of 20 nm at increasing time steps, i.e., at 0.1
sec, 0.125 sec, 0.2 sec and 0.25 sec. Initially at 0.1 sec, velocity in artery region is 4.47 m/sec which
increases to 4.7 m/sec at 0.125 sec. Later again it starts decreasing. The drug particle reaches the
tumor and dosage of drug increases continuously following cardiac cycle. However the flow
velocity of blood tissue and tumor regions is less compared to artery region because there is
obstruction for the flow of the blood at the tissue-tumor region.

0.1sec

0.125sec

0.2sec

0.25sec

Figure 12 : Velocity Distribution for Particle Size of 30 nm
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The Figure 12 shows the flow of drug particle of 30 nm at increasing time steps, i.e., at 0.1
sec, 0.125 sec, 0.2 sec and 0.25 sec. Initially at 0.1 sec, velocity in artery region is 3.99 m/sec which
increases to 4.7 m/sec at 0.125 sec. Later again it starts decreasing.
The drug particle reaches the tumor and dosage of drug increases continuously following
cardiac cycle. However the flow velocity of blood tissue and tumor regions is less compared to
artery region because there is obstruction for the flow of the blood at the tissue-tumor region. As
size of the drug particle increase, the velocity decreases.

0.1sec

0.125sec

0.2sec

0.25sec

Figure 13 : Velocity Distribution for Particle Size of 50nm
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The Figure 13 shows the flow of drug particle of 50 nm at increasing time steps, i.e., at 0.1
sec, 0.125 sec, 0.2 sec and 0.25 sec. Initially at 0.1 sec, velocity in artery region is 3.99 m/sec which
increases to 4.7 m/sec at 0.125 sec. Later again its starts decreasing.
The drug particle reaches the tumor and dosage of drug increases continuously following
cardiac cycle. However the flow velocity of blood tissue and tumor regions is less compared to
artery region because there is obstruction for the flow of the blood at the tissue-tumor region. As
size of the drug particle increases the velocity decreases. This variation can be seen for particle
sizes of 20nm, 30nm and 50nm.

4.4 Effect of Particle Size on Velocity Magnitude (Center of the Tumor)
To observe velocity at the center of the tumor for varying particle sizes, a point probe is
considered at the center of the tumor as shown in Figure 14. A point is considered at center of the
tumor as shown in Figure 14 and velocity at the center of the tumor region is compared with varying
sizes of particle diameter (Table 4) as plotted in Figure 15. Velocity at the center of the tumor region
is compared with varying sizes of particle diameter as plotted in Figure 15.

Figure 14 : Point Probe at the Center of the tumor

Table 4 : Data Showing Velocity Distribution
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Size(nm)/Time(sec)
0.1
0.125
0.2
0.25

20
0.042
0.075
0.033
0.00052

30
0.042
0.075
0.032
0.00052

50
0.042
0.075
0.032
0.00052

0.08
100nm
0.07
0.06

VELOCITY (M/SEC)

1mi

20 nm
30nm
50nm

50nm
30nm
20nm

0.05
0.04
100 nm
1 mi

0.03
0.02
0.01
0
0

0.05

0.1

0.15
TIME (SEC)

0.2

0.25

0.3

Figure 15 : Velocity Plot at the Center of the Tumor
The flow velocity of blood tissue and tumor regions is less compared to artery region.
Velocity magnitude is following the cardiac cycle. Velocity changed when particle diameter
changed from 100nm to 50nm and remained same for 20nm, 30nm and 50nm. No further changes
are noticed for sizes higher than 100 nm and smaller than 50nm.
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4.5 Effect of Drug Particle Density
From Figure 16 it is observed that the lower the density, higher is the velocity. Decrease in
particle diameter and density as a combination could prompt us with better penetration effect of
the drug to the tumor.

7

Density=1970kg/m^
3

Velocity (m/sec)

6

Density=1031kg/m^
3

5
4
3
2
1
0
0

0.05

0.1

0.15

0.2

0.25

0.3

Time(sec)
Figure 16 : Effect of Drug Particle Density
4.5 Particle Accumilation
Only velocity cannot assure us to find out the effect of drug in the region of tumor. Particle
volume distribution at tissue and tumor region analysis gives better idea to explain more about
uptake of drug (Table 5).
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Table 5 : Data Showing Particle Volume
Tissue-Tumor Region
Size /
Time (sec) 50nm
30nm
0.1
0.125
0.2
0.25
0.1
0.125
0.2
0.25

20nm

8452
13038
17345
22368
24754
26925
30024
33876
Tumor Region
4910.5
4110.4
10175
10281
22007
16008
21967
22362

10nm

10551
22778
33521
42042

11012
32656
41292
49532

5642
11667
22325
24177

7977.4
15408
26223
23648

Figure 17 shows particle volume variation with respect to time for different sizes of particle.
Amount of drug accumulated near tissue-tumor region increases with time. Rate of
accumulation is higher with decrease in drug particle size.

Tissue-tumor Region
60000

Particle Volume

50000
40000
50nm
30000

30nm
20nm

20000

10nm
10000
0
0

0.05

0.1

0.15

0.2

0.25

0.3

Time (sec)
Figure 17 : (a) Particle Volume Vs Time for Different Particle Size
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Figure 18 shows particle volume variation at tumor region with respect to time for different
sizes of particle. However, particle accumulation at the tumor region also increases till 0.2 sec and
later decreases for sizes of 10nm, 20nm and 50nm. There is increase in amount of drug after 0.2 sec
for a 30nm size particle.

Tumor Region
30000

25000

Particle Volume

20000

50nm

15000

30nm
20nm
10000

10nm

5000

0
0

0.05

0.1

0.15

0.2

0.25

0.3

Time (sec)

Figure 18 : (b) Particle Volume Vs Time for Different Particle Size
4.6 Polymer Coating
The polymers are used to deliver the drug to the target region. Biodegradable polymers are
generally used to deliver the drugs to a specific region of the body as they degrade with a constant
rate of drug release. Multifunctional particles are composed of drugs encapsulated with a layer of
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polymer. Polymer coating makes the particle as a carrier and prevents from dissolving in
bloodstream. The computational data that is discussed under Section 3.5 and tabular data from
Table 6 are used to discuss the results in this section.
Table 6 : Data Showing Particle Volume after Polymer Coating
Tissue-Tumor region
ratio(d:p)/Time(sec) 1:8
1:65
1:120
0.1
2.35E+05
2.41E+05 1.16E+05
0.125
1.89E+05
1.83E+05 1.78E+05
0.2
2.65E+05
2.30E+05 2.14E+05
0.25
4.67E+05
3.81E+05 3.97E+05
Tumor region
0.1
13172
10250
12496
0.125
18934
18771
19616
0.2
31910
28936
34440
0.25
28936
32121
30710

Figure 19 shows that initially the amount of drug reaching the tissue-tumor region
decreased; later, as time goes on,the amount of drug increased except for 1:120 ratio where it
increased continuously from initial state.

Tissue_Tumor region
5.00E+05
4.50E+05

Particle volume

4.00E+05
3.50E+05
3.00E+05
2.50E+05
2.00E+05
1.50E+05

1:8
1:65
1:120

1.00E+05
5.00E+04
0.00E+00
0

0.05

0.1

0.15

0.2

0.25

0.3

Time(sec)
Figure 19 : (a) Particle Volume Vs Time for Different Drug-Polymer Coating Ratios
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Whereas for tumor region, the amount of drug near tumor region increased at initial stage
only and a sudden drop at 0.25 sec is shown in Figure 20. For a drug-polymer ratio of 1:120 the
amount of drug reaching the tumor is much higher than remaining.

Tumor region
40000
35000

Particle volume

30000
25000
20000
15000
10000

1:8
1:65
1:120

5000
0
0

0.05

0.1

0.15

0.2

0.25

0.3

Time(sec)
Figure 20 : (b) Particle Volume Vs Time for Different Drug-Polymer Coating Ratios
4.7 Uptake of the Drug
Initially mass source term is deactivated for all the three cases and later it is activated
for 80% and 50% of cases to observe the uptake of the drug. From Figure 21 it is clear that
there is decrease in particle count at tumor region for the negative value of mass source term;
i.e., there is uptake of drug at tumor region (Table 7).
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Figure 21 : Uptake of the Drug
Table 7 : Data Showing Particle Count
Mass Term/ Time (sec)
0.1
0.125
0.2
0.25

Mass Term Off
446.88
2177
6508.2
8248.1

80%
446.88
1568.2
5229.9
6344.1

50%
446.88
2037.4
5933.6
7389.8

Figure 22 shows uptake of drug with respect to time. As time increases the amount of
drug increases but there is decrease in particle count when mass source term is activated.
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9000
8000
mass
source term
off

7000

Particle Count

6000

80%

5000
4000

50%

3000
2000
1000
0
0

0.05

0.1

0.15

0.2

0.25

0.3

Time(sec)

Figure 22 : Uptake of Drug with Respect to Time

Chapter 5: CONCLUSION
Conclusion:
A computational simulation model has been developed for analyzing multifunctional and selective
drug particle delivery to a targeted tissue-tumor region. The computational analysis is done by
solving governing equations of blood flow dynamics based on Navier-Stokes equations and mass
species transport based on Lagrangian particle flow equations. The diffusion considered in the
capillary-tissue regions is based on Brinkman’s model. Analysis of blood flow is performed using
experimentally derived cardiac input as inflow and considering the blood as Non-Newtonian in
nature, which is closer to reality.
Sensitivity of drug particle types and size on the delivery of the drugs to the target region is
analyzed. The simulation analysis results show that the decrease in particle diameter and density
as a combination could prompt us with better penetration effect of the drug to the tumor. The
higher the polymer coating over the drug increases the particle volume near the targeted region.
Drug uptake in the tumor region is also analyzed.
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